The main mechanism HSP90 inhibitors acted on cancer cells is mediated by inflammation and PCD, and similar events also have been found in ischemic diseases, neurodegenerative diseases, and others [7, 8, 46] (Fig. 2). This evidence concerns the gene HSP90AB1 and cancer.